Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Krystal Biotech Inc Market Cap
From what 4 stock analysts predict, the share price for Krystal Biotech Inc (KRYS) might increase by 47.18% in the next year. This is based on a 12-month average estimation for KRYS. Price targets go from $150.00 to $180.00. The majority of stock analysts believe KRYS is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 4 Wall Street analysts have assigned KRYS 4 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Krystal Biotech Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on KRYS. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| gavin clark gartner Evercore ISI | Buy | $168.0 | maintained | Feb 2, 2024 |
| dae gon ha Stifel Nicolaus | Buy | $150.0 | maintained | Jan 25, 2024 |
| joshua schimmer Cantor Fitzgerald | Buy | $180.0 | rated | Dec 13, 2023 |
| ritu baral TD Cowen | Buy | $160.0 | rated | Dec 11, 2023 |
| andrea tan Goldman Sachs | Buy | $160.0 | initiatedcoverage | Nov 20, 2023 |
| geulah livshits Chardan Capital | Buy | $153.0 | reiterated | Nov 6, 2023 |
| joseph pantginis H.C. Wainwright | Buy | $139.0 | reiterated | Nov 6, 2023 |
| carly kenselaar Citi | Buy | $160.0 | reiterated | Nov 6, 2023 |
| alec stranahan Bank of America Securities | Buy | $140.0 | reiterated | Nov 6, 2023 |
| caroline palomeque Berenberg Bank | Buy | $154.0 | initiatedcoverage | Oct 25, 2023 |
| madhu kumar Goldman Sachs | Buy | $155.0 | maintained | Jun 25, 2023 |
| debjit chattopadhyay Guggenheim | Buy | $130.0 | maintained | May 22, 2023 |
| raju prasad William Blair | Buy | None | maintained | May 22, 2023 |
| whitney ijem Canaccord Genuity | Buy | $114.0 | maintained | Feb 28, 2022 |
| soumit roy JonesTrading | Hold | None | rated | Jul 23, 2021 |
| lina kaminski JonesTrading | Buy | $97.0 | reiterated | Jul 2, 2021 |
| justin zelin BTIG | Buy | $100.0 | reiterated | Nov 11, 2020 |
| david hoang SMBC Nikko | Buy | $73.0 | initiatedcoverage | Mar 12, 2020 |
| graig suvannavejh Mizuho Securities | Hold | $60.0 | initiatedcoverage | Sep 24, 2019 |
| elemer piros Roth Capital | Buy | $67.0 | maintained | Jun 24, 2019 |
Krystal Biotech, Inc., a biotechnology company, develops and commercializes genetic medicines for patients with rare diseases in the United States. It develops beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa; KB105 for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for netherton syndrome; and KB407 for Cystic Fibrosis. The company also develops KB408 for Alpha-1 antitrypsin deficiency; and KB301 for aesthetic skin conditions. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
When did it IPO
2017
Staff Count
210
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Krish S. Krishnan M.B.A., M.S.
Market Cap
$3.20B
In 2023, KRYS generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that KRYS's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
ABCB-USD
$45.92
NWL-USD
$7.67
FLNC-USD
$17.01
MGRC-USD
$128.51
ARCB-USD
$138.8
ACLX-USD
$60.5
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
